KRT5 and neoplasm: Consistent with overrepresentation of a basal phenotype, a number of immunohistochemical (IHC) markers have been shown to be of value in assessing BRCA1 tumor phenotype in female patients, including estrogen receptor (ER), progesterone receptor (PR), human Epidermal Growth Factor Receptor 2 (HER2), p53, cytokeratin 5/6 (CK5/6), cytokeratin 14 (CK14), cytokeratin 17 (CK17), and epidermal growth factor receptor (EGFR) [4]-[8].